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Evidence in Colombia of 625G>A polymorphism in the short chain acyl-CoA
dehydrogenase gene, a variation which could cause glutaric aciduria
in our populations
JOSÉ HENRY OSORIO, PhD*
SUMMARY
Introduction: Short-chain acyl-CoA dehydrogenase (SCAD) is a homotetrameric mitochondrial flavoenzyme that
catalyzes the initial reaction in short-chain fatty acid β-oxidation. The SCAD gene is located on chromosome 12q22 and is
approximately 13 kb long with 10 exons and 1236 nucleotides of coding sequence. H reditary SCAD deficiency has been
reported and only a few cases of this disorder have been described.
Objective: The present study was conducted to determine the possible presence of the 625G>A variation in the short-
chain acyl-CoA dehydrogenase gene in Caldas (Colombia), given that variations 625G>A and 511C>T are present in 14% of
some studied populations; thereby sometimes causing its deficiency.
Methods: This is a descriptive study; blood samples from three-hundred adult volunteers were tested for 625G>A
polymorphism, analysing the polymerase chain reaction amplified cDNA, using a single-stranded conformation polymorphism
assay. The results were confirmed by direct bidirectional cycle sequencing using DNA from the positive persons.
Results: The polymorphism was identified and confirmed in four healthy persons.
Conclusion: This is evidence of the presence of 625G>A polymorphism in the short-chain acyl-CoA dehydrogenase gene
in Colombia, meaning that some people in our populations can be at risk of suffering SCAD deficiency and its main complication:
the ethylmalonic aciduria.
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Evidencia del polimorfismo 625G>A en el gen de la acil-CoA deshidrogenasa de cadena corta en Colombia, una
variación que podría causar aciduria glutárica en algunas  poblaciones del país
RESUMEN
Introducción: La acil-CoA deshidrogenasa de cadena corta (SCAD) es una flavoenzima homotetramérica mitocondrial que
cataliza la reacción inicial de la â-oxidación de los ácidos grasos de cadena corta. El gen SCAD se ubica en el cromosoma 12q22,
con una longitud de 13 kb, con 10 exones y 1236 nucleótidos de secuencia codificadora. Se ha informado la  deficiencia
hereditaria de SCAD  y se han descrito pocos casos de la deficiencia.
Objetivo: El presente estudio buscó determinar la posible presencia del polimorfismo 625G>A en Caldas, Colombia, debido
a que las variantes 625G>A y 511C>T en el gen de la acil-CoA deshidrogenasa de cadena corta están presentes en 14% de
algunas poblaciones estudiadas, causando algunas veces su deficiencia.
Métodos: El presente estudio es descriptivo; se estudiaron muestras de sangre de 300 voluntarios para el polimorfismo
625G>A mediante la técnica de polimorfismo de conformación de la cadena simple, con  ADN amplificado por reacción en
cadena de la polimerasa. Los resultados se confirmaron  por secuenciación.
Resultados: El polimorfismo se identificó  en cuatro personas aparentemente sanas.
Conclusión: Existe evidencia de la presencia del polimorfismo 625 G>A en el gen de la acil-CoA en Colombia, lo que significa
que algunas personas en las  poblaciones del país pueden estar en riesgo de sufrir deficiencia de SCAD y su principal
complicación, la aciduria etilmalónica.
Palabras claves: Acil-CoA deshidrogenasa de cadena corta; Polimorfismo 625G>A; Aciduria etilmalónica;
β-oxidación.
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All the currently identified mitochondrial fatty acid
(FA) β-oxidation defects are autosomal recessive. The
clinical manifestations result from the inability of FA-
oxidising tissues to keep up with increased energy
demands; therefore, target organs of FA oxidation
defects include skeletal and cardiac muscles in addition
to the liver1. Hypoketotic hypoglycaemia is present in
nearly all the defects, and usually occurs following an
intercurrent illness, but may occasionally be seen after
a short fast. In general, FA oxidation disorders should
always be included in the differential diagnosis of
unexplained hypoglycaemia, metabolic acidosis, Reye’s
like syndrome, myopathy, recurrent myoglobinuria, and
cardiomyopathy2. Laboratory findings reinforce the
clinical diagnosis, levels of intermediary metabolites in
urine (glucose, ketone bodies, lactate, pyruvate), and
blood (non-sterified FA)3; urinary organic acid profile4;
body fluids and tissue acylcarnitine analysis5; enzyme
measurement and pathway intermediates in cultured
cells and leukocytes6,7, and DNA analysis8 are used to
confirm the diagnosis of any alteration.
Short-chain acyl-CoA dehydrogenase deficiency is
a poorly characterized mitochondrial fatty acid β-
oxidation disorder with a very variable clinical picture
and at least 35 inactivating mutations and some
polymorphic variants have been reported in the SCAD
gene9. Hereditary SCAD deficiency was first reported
in 198410 and only few cases of this disorder have been
described for either classic SCAD deficiency or variant
SCAD10-13. A clinically reliable diagnosis requires either
a muscle biopsy for the measurement of the enzymatic
SCAD activity or molecular genetic analysis of the
SCAD gene, both only available in research laboratories.
This situation is further complicated by the presence of
the mainly two variants (625 G>A and 511C>T) in the
SCAD gene that are frequent in the European population,
and have been reported to confer disease susceptibility14.
In the 625G>A variation the polymorphic site is a
transition from G to A at position 625 (A625) of the
coding region of the cDNA, changing a glycine to serine
at amino acid position (G185S) of the precursor protein.
The variant 625G>A has been shown to be associated
with ethymalonic aciduria and other biochemical
findings15. Because urinary ethymalonic acid (EMA)
elevation most likely reflects a cellular accumulation of
butyryl-CoA16, which is secondary to reduced SCAD
catalytic activity, these patients are correctly considered
as possibly having SCAD deficiency.
Despite the fact that most patients with EMA aciduria
have not had their SCAD activity determined, an
association between elevated EMA and SCAD has
been documented by the presence of either or both of
two SCAD gene susceptibility variations in 69% of
patients with EMA aciduria17. The 625G>A variant
shows homozygous prevalence of 60%, as SCAD
protein presents reduced stability compared to the con-
trol SCAD protein18. As SCAD is a key enzyme in the
oxidation of fatty acids, which serve as substrates for
the gluconeogenesis (Figure 1), reduced SCAD activity
because of the 625G>A variant for fasting hypogly-
caemia, and ethymalonic aciduria as shown in the
SCAD deficiency. The present study was conducted to
determine the possible presence of the 625G>A variation
in the short-chain acyl-CoA dehydrogenase gene in
Caldas, Colombia, as the 625G>A and 511C>T variations
are present in 14% of some populations studied,
sometimes causing its deficiency.
MATERIALS AND METHODS
The present study is descriptive. Blood samples used
in this study were from 300 adult, healthy volunteers
between 18 and 49 years of age (120 men and 180
women), all born in Caldas, Colombia, apparently none
suffering from any inherited inborn error of metabolism.
According to the number of persons visiting our
laboratory, samples were collected between January
2006 and January 2009, which means that samples were
obtained by convenience, and all participants signed
written consent.
Blood samples were extracted in tubes containing
EDTA. DNA extraction was performed according to
Gustafson et al.19, with some modifications. The
polymorphism was identified by comparing the
polymerase chain reaction (PCR) and amplified cDNA
from a previously studied person carrying the
polymorphism with the apparently healthy volunteers. A
single-stranded conformation polymorphism (SSCP)
assay, based on the following primers was used: Sense
primer: 5’-GCAGCTCTGAGAAAACCAC. Antisense
primer: 5’-ATGTCC AGGGTTTGCTGT. PCR
Conditions: 3 min at 94°C, 40 sec at 94°C, 30 sec at
55°C, and 2 min at 72°C for 35 cycles with 500 ng of
purified genomic DNA as template and 75 ng of each
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primer. When DNA fragments were subjected to
electrophoresis in 8% acrilamide/bisacrilamide (19:1),
7.5 M urea gel, at room temperature for 3 hours, the
single-base change at position 625 was clearly detected
after silver stain. The results were confirmed by direct
bidirectional cycle sequencing using DNA.
According to Article 11 on its literal a from Resolution
N° 8430 promulgated by the Ministry of Health for
Scientific, technical and administrative guidelines for
health research, the present study is considered without
risk. The study was approved by the corresponding
ethics committee.
RESULTS
After analyzing DNA samples from the 300
participants, the polymorphism was identified in four
apparently healthy adult volunteers -all in heterozygosis.
The first case was a 21-year-old male who was born
from non-consanguineous parents, another two indivi-
duals were identified as carriers of the polymorphism;
they are the parents of a family who presented two
cases of sudden infant death after two consecutive
pregnancies and they are cousins. After a third
pregnancy, a baby was born and after 2 years she is still
alive without problems; she did not present the 625G>A
polymorphism. A fourth person was identified as carrying
the polymorphism, an apparently normal 22-year-old
woman. The four persons are from families without
antecedents of any disease that could be related to some
fatty acid oxidation disorder; the acylcarnitine analysis
was normal for all of them.
DISCUSSION
Colombia is divided into 35 regions with an
approximate total population of 45-million inhabitants,
presenting racial mixture. Data obtained from the 2005
census shows that Caldas (a Colombian region) has a
population of 968,740 inhabitants distributed within 29
municipalities20. For us, it is very important to detect the
presence of this polymorphism to demonstrate the
presence of fatty-acid-oxidation inherited diseases
among us, and it is a valuable contribution for the future
u derstanding of geographical distribution and ethnic
origin elucidation of SCAD deficiency, as no previous
reports have been published showing the presence of
this polymorphism in these countries, while being mainly
reported in Europe and the United States21. The first
person presenting this variant in our study has a very
interesting genetic charge for these kinds of works, as
















Figure 1. Mitochondrial β-oxidation of fatty acids. Butyric acid accumulates when degradation of
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and his mother is from the north of Antioquia, a place
characterized by the presence of a strong Spaniard
white genotype. The other 3 persons are from the centre
of the country.
There are reports of ethnic differences observed
with respect to the 625G>A variant, while the allele
frequency was similar between Caucasians and
Hispanics (25 and 30%, respectively), African-
Americans and Asians carried the 625G>A variant less
frequently (9 and 13%, respectively)22. Corydon et
al.14, found the 625A variant allele in homozygous form
in 60% of 135 patients with elevated EMA excretion,
analysed because a suspicion of a metabolic disorder,
compared with 7% occurrence in the general population.
That is why, since about 10-14% of the general population
is homozygous 625G>A or 511C>T or compound
heterozygous for both, it is necessary to have some
other indication that they are disease-associated. It is
generally accepted that some biochemical analysis can
be performed to confirm if the person carrying the
polymorphism is suffering the disease. Because these
patients are phenotypically diverse, the analysis of blood
acylcarnitines is a good tool for diagnosing SCAD
deficiency. The acylcarnitine profile in these patients is
characterized by high blood concentrations of
butyrylcarnitine (C4-acylcarnitine). The acylcarnitine
profile for our patients was normal; hence, they are
carrying the polymorphism without suffering the disease.
CONCLUSION
Short-chain acyl-CoA dehydrogenase (SCAD)
deficiency is a clinically heterogeneous disorder. The
clinical phenotype varies from fatal metabolic
decompensation in early life to subtle adult onset, and
some patients remain asymptomatic. Two mutations
(511C>T; 625G>A) have been described in exons 5 and
6 of the SCAD gene, respectively. These variants are
not true disease-causing mutations but can confer disease
susceptibility because they alter the structural and
catalytic properties of the SCAD protein. Although the
prevalent finding for SCAD deficiency is neurological
abnormalities, such as hypotonia and seizures accom-
panying general developmental delay, the population of
patients with ethylmalonic aciduria with a high frequency
of the 625A variant allele in the homozygous form also
showed diverse phenotypes, typically neuromuscular
symptoms, and hypoglycaemia. The acylcarnitine analysis
is an important tool in diagnosing the disease, given that
a high concentration of C4-acylcarnitine is consistent
with a biochemical diagnosis of SCAD deficiency. This
kind of study is important for us because it shows the
presence of mutations or polymorphisms, which can
cause some metabolic alterations related to enzymatic
dysfunction of some biochemical ways, not reported or
treated among us. We need to continue studying our
populations to know the real frequency of this
polymorphism because the principal studies have been
performed mainly in Caucasoid populations.
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